Drugs / DS-2330b
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03305471 | Aug 2017 → Jan 2019 | hyperphosphatemia | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-2330b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03305471 ↗ |
| Route | Oral | “14-day repeated oral doses of DS-2330b PIB” NCT03305471 ↗ |